Want to see GB:HEMO full AI Analyst Report?
HEMO Stock Chart & Stats
556.00 p
21.00 p(2.89%)
At close: 4:00 PM EDT
556.00 p
21.00 p(2.89%)
Day’s Range― - ―
52-Week Range356.00 p - 1,220.00 p
Previous CloseN/A
Volume7.73K
Average Volume (3M)23.65K
Market Cap
£39.04M
Enterprise Value45.81M
Total Cash (Recent Filing)£4.58M
Total Debt (Recent Filing)£1.85M
Price to Earnings (P/E)―
Beta-0.42
Next Earnings
Apr 23, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.81
Shares Outstanding6,896,786
10 Day Avg. Volume18,922
30 Day Avg. Volume23,647
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)21.26
Price to Sales (P/S)0.00
P/FCF Ratio-7.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt ReductionReducing total debt provides some improvement in financial flexibility, even though leverage remains elevated. Continued debt reduction could lower financing pressure and preserve more resources for research and development, helping the company manage its capital needs over the next several quarters.
Improved Cash OutflowsThe reduction in operating and free cash outflows suggests some progress in controlling cash consumption. Although cash flow remains negative, sustaining this improvement would extend available funding and give management more time to advance candidates before requiring additional external capital.
Focused Hematology PlatformA defined focus on blood-forming stem cells and hematology/oncology gives the company a specialized development direction rather than an unfocused biotechnology strategy. Concentrating resources in related therapeutic areas may support deeper expertise and more coherent pipeline development.
Bears Say
No Reported RevenueThe absence of reported revenue indicates that the business has not yet established a commercial earnings base. Without product, licensing, or other top-line generation, ongoing research spending must be supported externally, leaving financial performance highly dependent on future development progress.
Widening LossesThe widening net loss shows that operating costs and development spending are not yet translating into improving profitability. Persistent losses can accelerate reliance on outside funding and make it harder to build a durable financial base while clinical and research programs remain in development.
Leverage And Shrinking EquityDebt above equity and the sharp reduction in the equity base leave a smaller balance-sheet cushion against continued losses. This weakens financial resilience, increases dependence on financing, and may constrain the company’s ability to fund development without further capital support.
HemoGenyx Pharmaceuticals Plc News
HEMO FAQ
What was HemoGenyx Pharmaceuticals Plc’s price range in the past 12 months?
HemoGenyx Pharmaceuticals Plc lowest share price was 356.00 p and its highest was 1220.00 p in the past 12 months.
What is HemoGenyx Pharmaceuticals Plc’s market cap?
HemoGenyx Pharmaceuticals Plc’s market cap is £39.04M.
When is HemoGenyx Pharmaceuticals Plc’s upcoming earnings report date?
HemoGenyx Pharmaceuticals Plc’s upcoming earnings report date is Apr 23, 2027 which is in 174 days.
How were HemoGenyx Pharmaceuticals Plc’s earnings last quarter?
HemoGenyx Pharmaceuticals Plc released its earnings results on Sep 28, 2026. The company reported -1.017 p earnings per share for the quarter.
Is HemoGenyx Pharmaceuticals Plc overvalued?
According to Wall Street analysts HemoGenyx Pharmaceuticals Plc’s price is currently Overvalued.
Does HemoGenyx Pharmaceuticals Plc pay dividends?
HemoGenyx Pharmaceuticals Plc does not currently pay dividends.
What is HemoGenyx Pharmaceuticals Plc’s EPS estimate?
HemoGenyx Pharmaceuticals Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does HemoGenyx Pharmaceuticals Plc have?
HemoGenyx Pharmaceuticals Plc has 6,896,786 shares outstanding.
What happened to HemoGenyx Pharmaceuticals Plc’s price movement after its last earnings report?
HemoGenyx Pharmaceuticals Plc reported an EPS of -1.017 p in its last earnings report. Following the earnings report the stock price went up 3.236%.
Which hedge fund is a major shareholder of HemoGenyx Pharmaceuticals Plc?
Currently, no hedge funds are holding shares in GB:HEMO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HemoGenyx Pharmaceuticals Plc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.01%
12-Months-Change
Fundamentals
Return on Equity
-409.57%
Trailing 12-Months
Asset Growth
121.61%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc is a preclinical biotechnology company dedicated to the discovery, advancement, and commercialization of innovative therapies for various blood diseases. The firm's pipeline is heavily focused on creating novel solutions for the bone marrow and hematopoietic stem cell (BM/HSC) transplant sector. Key developments include a CDX bi-specific antibody, engineered to target challenging conditions such as relapsed/refractory acute myeloid leukaemia (R/R AML), specific forms of acute lymphoblastic leukaemia, and myelodysplastic syndrome, aiming to replace traditional chemotherapy or radiation for transplant conditioning. Also under development is HEMO-CAR-T therapy, which utilizes chimeric antigen receptor T-cells to effectively identify and destroy human acute myeloid leukaemia cells in laboratory and in vivo settings. Additionally, the company is advancing Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapeutic specifically for BM/HSC transplant procedures. Founded in 2012, Hemogenyx Pharmaceuticals is headquartered in London, United Kingdom.
Technical Analysis
ImmuPharma
―
Open Orphan Plc
―
Poolbeg Pharma Ltd.
―
Arecor Therapeutics PLC
―
Aptamer Group Plc
―